The B-cell lymphoma 2 (BCL2)-inhibitors, ABT-737 and ABT-263, are substrates for P-glycoprotein

Biochemical and Biophysical Research Communications

Volumn 408, Issue 2, 2011, Pages 344-349

  Vogler, Meike ^a   Dickens, David ^b   Dyer, Martin J S ^a   Owen, Andrew ^b   Pirmohamed, Munir ^b   Cohen, Gerald M ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

ABT 263 (Navitoclax); ABT 737; BCL2; Drug resistance; P glycoprotein

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; 4 [4 [2 (4 CHLOROPHENYL) 5,5 DIMETHYL 1 CYCLOHEXEN 1 YLMETHYL] 1 PIPERAZINYL] N [4 [3 MORPHOLINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 (TRIFLUOROMETHYLSULFONYL)BENZENESULFONYL]BENZAMIDE; GLYCOPROTEIN P; PROTEIN BCL 2; TARIQUIDAR; VERAPAMIL;

ANIMAL CELL; ANIMAL CELL CULTURE; APOPTOSIS; ARTICLE; B CELL LYMPHOMA; CHRONIC LYMPHATIC LEUKEMIA; DRUG PROTEIN BINDING; DRUG TRANSPORT; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; ISOTOPE LABELING; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANILINE COMPOUNDS; ANIMALS; BIPHENYL COMPOUNDS; CELL LINE; DOGS; NITROPHENOLS; P-GLYCOPROTEIN; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-BCL-2; SUBSTRATE SPECIFICITY; SULFONAMIDES;

EID: 79955668070     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.04.043     Document Type: Article

References (27)

1. Adams J.M., Cory S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 2007, 26:1324-1337.
2. Youle R.J., Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nat. Rev. Mol. Cell Biol. 2008, 9:47-59.
3. Vogler M., Dinsdale D., Dyer M.J., Cohen G.M. Bcl-2 inhibitors: small molecules with a big impact on cancer therapy. Cell Death Differ. 2009, 16:360-367.
4. Oltersdorf T., Elmore S.W., Shoemaker A.R., Armstrong R.C., Augeri D.J., Belli B.A., Bruncko M., Deckwerth T.L., Dinges J., Hajduk P.J., Joseph M.K., Kitada S., Korsmeyer S.J., Kunzer A.R., Letai A., Li C., Mitten M.J., Nettesheim D.G., Ng S., Nimmer P.M., O'Connor J.M., Oleksijew A., Petros A.M., Reed J.C., Shen W., Tahir S.K., Thompson C.B., Tomaselli K.J., Wang B., Wendt M.D., Zhang H., Fesik S.W., Rosenberg S.H. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005, 435:677-681.
5. Tse C., Shoemaker A.R., Adickes J., Anderson M.G., Chen J., Jin S., Johnson E.F., Marsh K.C., Mitten M.J., Nimmer P., Roberts L., Tahir S.K., Xiao Y., Yang X., Zhang H., Fesik S., Rosenberg S.H., Elmore S.W. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 2008, 68:3421-3428.
6. Park C.M., Bruncko M., Adickes J., Bauch J., Ding H., Kunzer A., Marsh K.C., Nimmer P., Shoemaker A.R., Song X., Tahir S.K., Tse C., Wang X., Wendt M.D., Yang X., Zhang H., Fesik S.W., Rosenberg S.H., Elmore S.W. Discovery of an orally bioavailable small molecule inhibitor of prosurvival B-cell lymphoma 2 proteins. J. Med. Chem. 2008, 51:6902-6915.
7. Yecies D., Carlson N.E., Deng J., Letai A. Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1. Blood 2010, 115:3304-3313.
8. Fletcher J.I., Haber M., Henderson M.J., Norris M.D. ABC transporters in cancer: more than just drug efflux pumps. Nat. Rev. Cancer 2010, 10:147-156.
9. Ambudkar S.V., Dey S., Hrycyna C.A., Ramachandra M., Pastan I., Gottesman M.M. Biochemical, Cellular, and pharmacological aspects of the multidrug transporter. Annu. Rev. Pharmacol. Toxicol. 1999, 39:361-398.
10. Yang K., Wu J., Li X. Recent advances in the research of P-glycoprotein inhibitors. Biosci. Trends 2008, 2:137-146.
11. Fox E., Bates S.E. Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor. Expert Rev. Anticancer Ther. 2007, 7:447-459.
12. Friedenberg W.R., Rue M., Blood E.A., Dalton W.S., Shustik C., Larson R.A., Sonneveld P., Greipp P.R. Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95): a trial of the Eastern Cooperative Oncology Group. Cancer 2006, 106:830-838.
13. Abraham J., Edgerly M., Wilson R., Chen C., Rutt A., Bakke S., Robey R., Dwyer A., Goldspiel B., Balis F., Van Tellingen O., Bates S.E., Fojo T. A phase I study of the P-glycoprotein antagonist tariquidar in combination with vinorelbine. Clin. Cancer Res. 2009, 15:3574-3582.
14. Beck W.T., Mueller T.J., Tanzer L.R. Altered surface membrane glycoproteins in Vinca alkaloid-resistant human leukemic lymphoblasts. Cancer Res. 1979, 39:2070-2076.
15. Schinkel A.H., Wagenaar E., Mol C.A., Van Deemter L. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J. Clin. Invest. 1996, 97:2517-2524.
16. Ludescher C., Hilbe W., Eisterer W., Preuss E., Huber C., Gotwald M., Hofmann J., Thaler J. Activity of P-glycoprotein in B-cell chronic lymphocytic leukemia determined by a flow cytometric assay. J. Natl. Cancer Inst. 1993, 85:1751-1758.
17. Evers R., Kool M. L. van Deemter, H. Janssen, J. Calafat, L.C. Oomen, C.C. Paulusma, R.P. Oude Elferink, F. Baas, A.H. Schinkel, and P. Borst, Drug export activity of the human canalicular multispecific organic anion transporter in polarized kidney MDCK cells expressing cMOAT (MRP2) cDNA. J. Clin. Invest. 1998, 101:1310-1319.
18. Maynadie M., Matutes E., Catovsky D. Quantification of P-glycoprotein in chronic lymphocytic leukemia by flow cytometry. Leuk. Res. 1997, 21:825-831.
19. Del Gaizo Moore V., Brown J.R., Certo M., Love T.M., Novina C.D., Letai A. Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. J. Clin. Invest. 2007, 117:112-121.
20. Vogler M., Furdas S.D., Jung M., Kuwana T., Dyer M.J., Cohen G.M. Diminished sensitivity of chronic lymphocytic leukemia cells to ABT-737 and ABT-263 due to albumin binding in blood. Clin. Cancer Res. 2010, 16:4217-4225.
21. Vogler M., Dinsdale D., Sun X.M., Young K.W., Butterworth M., Nicotera P., Dyer M.J., Cohen G.M. A novel paradigm for rapid ABT-737-induced apoptosis involving outer mitochondrial membrane rupture in primary leukemia and lymphoma cells. Cell Death Differ. 2008, 15:820-830.
22. Martin C., Berridge G., Mistry P., Higgins C., Charlton P., Callaghan R. The molecular interaction of the high affinity reversal agent XR9576 with P-glycoprotein. Br. J. Pharmacol. 1999, 128:403-411.
23. Hann C.L., Daniel V.C., Sugar E.A., Dobromilskaya I., Murphy S.C., Cope L., Lin X., Hierman J.S., Wilburn D.L., Watkins D.N., Rudin C.M. Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2 in small cell lung cancer. Cancer Res. 2008, 68:2321-2328.
24. Tahir S.K., Yang X., Anderson M.G., Morgan-Lappe S.E., Sarthy A.V., Chen J., Warner R.B., Ng S.C., Fesik S.W., Elmore S.W., Rosenberg S.H., Tse C. Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737. Cancer Res. 2007, 67:1176-1183.
25. Vogler M., Butterworth M., Majid A., Walewska R.J., Sun X.M., Dyer M.J., Cohen G.M. Concurrent upregulation of BCL-XL and BCL2A1 induces 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia. Blood 2009, 113:4403-4413.
26. Svoboda-Beusan I., Kusec R., Bendelja K., Tudoric-Ghemo I., Jaksic B., Pejsa V., Rabatic S., Vitale B. The relevance of multidrug resistance-associated P-glycoprotein expression in the treatment response of B-cell chronic lymphocytic leukemia. Haematologica 2000, 85:1261-1267.
27. Xu H., Krystal G.W. Actinomycin D Decreases Mcl-1 Expression and Acts Synergistically with ABT-737 against Small Cell Lung Cancer Cell Lines. Clin. Cancer Res. 2010, 16:4392-4400.